A5074185199- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- HER2/EGFR in Cancer Research
- Angiogenesis and VEGF in Cancer
- PI3K/AKT/mTOR signaling in cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Advanced Chemical Sensor Technologies
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Asthma and respiratory diseases
- Medical Imaging and Pathology Studies
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer therapeutics and mechanisms
Sheba Medical Center
2016-2025
Tel Aviv University
2014-2024
The Radiosurgery Society
2023
Arthur M. Sackler Gallery
2021
Pulmonary Associates
2001-2017
TD Bank
2013
The University of Texas MD Anderson Cancer Center
2002-2009
Weatherford College
2008
AstraZeneca (United Kingdom)
2007
Park Plaza Hospital
2005
BackgroundAfatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade afatinib plus paclitaxel superior outcomes versus switching to chemotherapy alone acquiring resistance erlotinib/gefitinib and monotherapy.Patients methodsPatients relapsed/refractory disease following ≥1 line of chemotherapy, whose tumors had progressed...
Non-small cell lung cancer (NSCLC) is one of the leading causes cancer-related deaths worldwide. Common treatment modalities for NSCLC include surgery, radiotherapy, chemotherapy, and, in recent years, clinical management paradigm has evolved with advent targeted therapies. Despite such advances, impact systemic therapies advanced disease remains modest, and as such, prognosis patients poor. Standard are not without their respective toxicities there a clear need to improve both efficacy...
Abstract Purpose: Despite maximal therapy, surgically treated patients with stage I non-small cell lung cancer (NSCLC) are at risk for developing metastatic disease. Histopathologic findings cannot adequately predict disease progression, so there is a need to identify molecular factors that serve this purpose. Because the ErbB receptors play an important role in we analyzed expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, transforming α (TGFα), and HER2-neu as...
In recent years, the incidence of cutaneous melanoma has increased more than that any other cancer. Dacarbazine is considered gold standard for treatment, having a response rate 15% to 20%, but most responses are not sustained. Previously, we have shown short exposure primary cells dacarbazine resulted in upregulation interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF). The purpose present study was determine how long-term would affect their tumorigenic metastatic potential...
Background: Non-small cell lung cancer (NSCLC) is a common and highly lethal disease. As advanced treatment modalities are being developed, improved prognostication methods sought. L3 skeletal muscle index (L3SMI) alanine aminotransferase (ALT) levels accepted surrogate markers of sarcopenia related frailty. We aimed to evaluate the potential association these with NSCLC patients' survival. Methods: A retrospective, single-center study an cohort. L3SMI was calculated based on area computed...
Background Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC). Methods 125 consecutive aLCNEC were identified electronic databases 4 participating cancer centers. The divided into group A (patients who received ICI, n=41) and B did not receive n=84). Overall survival since disease diagnosis (OS DX) OS ICI initiation ICI) captured. Results With a median follow-up 11.8 months (mo) (IQR...
PURPOSE: To retrospectively identify radiographic characteristics of stage I non–small cell lung cancer (NSCLC) that may correlate with epidermal growth factor receptor (EGFR) or HER2 expression prognosis. MATERIALS AND METHODS: This study was approved by the institutional review board, waiver informed consent, and in compliance HIPAA regulations. Findings chest computed tomography (CT) were evaluated 72 patients who underwent resection pathologic NSCLC; tumor diameter, presence...
Abstract The outcome for patients with lung cancer has not changed significantly more than two decades. Several studies show that the overexpression of vascular endothelial growth factor (VEGF)/vascular permeability and epidermal (EGF) their receptors correlates clinical patients. However, trials agents target either these pathways alone have been disappointing. We hypothesize targeting both tumor its vasculature by simultaneously blocking VEGFR EGFR will improve treatment locoregional...
Purpose: Because of emergence resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for patients with lung cancer who lose sensitivity due new mutations or bypass mechanisms. We examined in animals and vitro an alternative therapeutic approach making use antibodies.Experimental Design: An osimertinib-sensitive animal model cancer, which rapidly develops drug resistance, has been employed. To overcome compensatory...
Abstract Purpose: Bone is a common site for breast cancer metastasis. Platelet-derived growth factor (PDGF) and PDGF receptors (PDGFR) are involved in the regulation of bone resorption. This study examined effects STI571 (imatinib mesylate), which inhibits PDGFR tyrosine kinase signaling, on human cells nude mice with consequent osteolysis. Experimental Design: Human MDA-MB-435 were injected into tibia female mice. Two weeks later treated p.o. water (control), daily STI571, weekly injection...